Translational Medicine in CNS Drug Development

Dr. Nomikos has more than 30 years of experience in neuropsychopharmacology and CNS therapeutics in both academia and the pharmaceutical/biotechnology industry, focusing on CNS translational and experimental medicine and clinical drug development in psychiatry and neurology. Dr. Feltner has more than 20 years of experience in drug development and translational medicine. He has held previous positions leading neuroscience development at Abbvie and leading Translational Medicine at Pfizer.

• 1. Translating animal models of obesity and diabetes to the clinic2. Biomarker-guided drug development for better defined early patient studies and clinical trial efficiency3. Modeling and simulation in the translational pharmacology of cns drugs4. Functional measurements of central nervous system drug effects in early human drug development5. Experimental medicine approaches in cns drug development6. New approaches in translational medicine for phase i clinical trials of cns drugs7. Translational approaches for antidepressant drug development8. Biomarker opportunities to enrich clinical trial populations for drug development in schizophrenia and depression9. Applications of neuroimaging biomarkers in cns drug development10. Pet occupancy and competition in translational medicine and cns drug development11. Stable isotope labeling kinetics in cns translational medicine: introduction to silk technology12. Applications of neurophysiological biomarkers in cns drug development: focus on psychoses13. Heart rate variability as a translational biomarker for emotional and cognitive deficits14. Drug discovery in psychiatry: time for human genome-guided solutions15. Use of cognition to guide decisions about the safety and efficacy of drugs in early-phase clinical trials16. Digital biomarkers in clinical drug development17. Lessons learned from public private partnerships and consortia: the adni paradigm18. Regulatory perspectives on the use of biomarkers and personalized medicine in cns drug development: the fda viewpoint19. Regulatory considerations for the use of biomarkers and personalized medicine in cns drug development: a european perspective20. Regulatory science objectives and biomarker qualification through public-private partnerships are critical to delivering innovative treatments for cns diseases21. The assessment of cognition in translational medicine: a contrast between the approaches used in alzheimer’s disease and major depressive disorder22. Translational medicine strategies in drug development for neurodevelopmental disorders23. Translational medicine strategies in drug development for mood disorders24. Translational medicine strategies in alzheimer’s disease drug development25. Experimental medicine models in generalized anxiety disorder and social anxiety disorder26. Translational medicine strategies in ptsd drug development27. Unmet medical needs in the treatment of depression and the clinical development of a differentiated antidepressant: a translational line of evidence28. Translating neurobiology into practice in tobacco, alcohol, drug, and behavioral addictions29. Translational medicine strategies for drug development for impulsive aggression30. Hypothesizing major depression as a subset of reward deficiency syndrome (rds) linked to polymorphic reward genes: considerations for translational medicine approaches for future drug development31. Traveling through the storm: leveraging virtual patient monitoring and artificial intelligence to observe, predict, and affect patient behavior in cns drug development